Navigation Links
Cyberonics Reports Fiscal 2014 First Quarter Results
Date:8/22/2013

Measures," in this release, the company refers to and makes comparisons with certain non-GAAP financial measures, including adjusted non-GAAP income from operations, adjusted non-GAAP net income, and adjusted non-GAAP income per diluted share.  Investors should consider non-GAAP measures in addition to, and not as a substitute for or superior to, financial performance measures prepared in accordance with GAAP.  Please refer to the attached non-GAAP reconciliation.

Results and objectives"Net sales in the first quarter of fiscal 2014 met our expectations and provides a good start to the fiscal year," commented Dan Moore, Cyberonics' President and Chief Executive Officer.  "Our U.S. sales team followed a record fourth-quarter performance with a near-record quarter in both unit sales and net product sales.  Estimates of new patient and replacement growth rates are consistent with those provided in our annual guidance.  International unit sales were well ahead of the first quarter of last year, with Europe in particular continuing the strong performance seen in fiscal 2013.

"Adjusted EBITDA for the first quarter was $25.6 million, and with our available cash and short-term investments of $131 million, the company is well-positioned to continue to deliver stockholder value with investments in next-generation products and stock repurchases.

"Our AspireSR™ clinical studies, E-36 and E-37, have both progressed this quarter.  Enrollment in E-36 is now complete, and the first five patients in our U.S.-based study, E-37, have received the AspireSR generator.  Further, we completed enrollment in our ANTHEM study, assessing Autonomic Regulation Therapy for patients with chronic heart failure.  We are pleased to have achieved each of these important clinical steps while continuing to grow our global epilepsy sales," concluded Mr. Moore.

Stock Repurchase UpdateDuring the recently completed quarter,
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. SPO Reports Results for Second Quarter 2013
2. Global IVIG Market Report 2013 Edition Research at MarketReportsOnline.com
3. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
4. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
5. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
6. Intercept Pharmaceuticals Reports Second Quarter 2013 Financial Results
7. Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update
8. Dyadic International Reports Second Quarter 2013 Financial Results
9. Microbes Market and Microbial Products Reviewed in New Research Report at ReportsnReports.com
10. Discovery Labs Reports Second Quarter 2013 Financial Results
11. Global Crop Protection Chemicals Market Till 2016 - Worldwide Research Report, Industry Share, Size, Trends, Analysis, Growth and Forecast 2012-2016: MarketResearchReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... cells, called photoreceptors, could hold the key to stopping ... diseases, Yale School of Medicine researchers report in the ... Several blinding disorders are known to cause ... comparative medicine and ophthalmology at Yale School of Medicine, ...
... , PHOENIX, Nov. 16 NutraCea (OTC: ... research and technology, announced today that Henk Hoogenkamp, a world ... meat processing industries, has agreed to act as an Executive ... results of research and development in various applications to further ...
... , BOSTON, Nov. 16 Hollis-Eden Pharmaceuticals, ... of its ongoing Phase I/II clinical trial with Apoptone® ... cancer or CRPC). Presented at the Molecular ... the AACR, NCI and EORTC, the poster is titled: ...
Cached Biology Technology:Finding a protective mechanism for retinal cells could save sight 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 2Henk Hoogenkamp, Accomplished Author and Food Ingredient Scientist, Joins NutraCea as Executive Advisor on the Utilization of Stabilized Rice Bran in Food Ingredient Applications 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference 4
(Date:4/20/2014)... 2014 -- Using corn crop residue to make ethanol ... more greenhouse gases than gasoline, according to a study ... . , The findings by a University of Nebraska-Lincoln ... can be used to meet federal mandates to ramp ... Corn stover -- the stalks, leaves and cobs in ...
(Date:4/18/2014)... researchers have published soil organic carbon sequestration rates. ... organic carbon can be sequestered by simply switching from ... there is a growing body of research with evidence ... cover crops, small grains, and forages may not be ... , "Some studies have shown that both moldboard and ...
(Date:4/18/2014)... team of researchers led by a University of California, ... a $7.5 million Department of Defense grant to uncover ... foundations for the predictable design of light-weight, tough and ... structures from plants and animals, including the mantis shrimp, ... systems have constructed over millions of years and coming ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4Mantis shrimp, toucan and trilobite, oh my 2Mantis shrimp, toucan and trilobite, oh my 3
... in the June issue of American Naturalist, Erika J. ... and Michael J. Donoghue (Yale University) explore how leafy, ... "The cactus form is often heralded as a striking ... in plants," write the authors. "A succulent, long-lived photosynthetic ...
... researcher in Washington, D.C., has been working toward tracking ... hepatitis C. , Dr. Maria Sjogren, a retired Army ... in treating liver disease, has enrolled 90 active-duty servicemembers ... Center. The virus, which affects the U.S. military at ...
... Max Planck scientists have identified a new strategy which ... was carried out by Prof. Jonathon Howard and Stefan ... Biology and Genetics in Dresden. The motor protein MCAK ... end of microtubules where it disassembles them. This is ...
Cached Biology News:Researcher studies, treats military with 'silent disease' 2Researcher studies, treats military with 'silent disease' 3Researcher studies, treats military with 'silent disease' 4
... Idaho Technologys R.A.P.I.D. System (Ruggedized Advanced ... real-time, PCR thermocycler designed for field ... environments. In addition to its ruggedness, ... sensitivity and specify as the LightCycler ...
... ES Cell Characterization Kit consists of two ... as well as four ES cell-specific antibodies ... • Stem cells have become the subject ... their therapeutic potential and because they raise ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Note: Evaluated for its amino acid acceptor activity ... acids Ala, Asp, Gly, Ile, Lys, Pro, Thr, ... Preparation Unit Definition: One unit will yield an ... of water (1 cm light path). ...
Biology Products: